Life Sciences

Cancer detection firm Oncimmune makes Germany acquisition

March 22, 2019

Nottingham-based cancer detection company Oncimmune Holdings has acquired a business in Germany for a total consideration of up to £4.11m. Dortmund-based Protagen Diagnostics AG develops precision medicine and patient stratification tools for pharmaceutical multinationals in both immuno-oncology and autoimmune disease. These tools support drug development,..

Where can Biogen turn after mammoth Alzheimer’s blow? The M&A table, analysts say

March 22, 2019

Biogen investors’ worst fears have come true with the failure of its phase 3 Alzheimer’s prospect, and now, it may be “buy or be bought” time for the Big Biotech. Thursday, Biogen and partner Eisai said they’d given up on their program for aducanumab—or, as..

Who’ll follow Sanofi CEO Olivier Brandicourt? The company’s eyeing candidates now

March 21, 2019

It’s been a tumultuous four years for Olivier Brandicourt at Sanofi, marked by restructuring, cost cuts, an asset swap and two M&A deals designed to upgrade the drugmaker’s rare disease business. What happens over the next four years is anybody’s guess, but the company’s working..

Novartis CEO: It’s Time to “Pivot Towards Transformational Innovation”

March 21, 2019

Vasant Narasimhan is bringing a unique brand of leadership to his job as CEO of Novartis (NVS). It’s not surprising when you hear about his unusual background and his path to the C-Suite. A Harvard-trained physician and former McKinsey & Company consultant, he worked for..

Thermo Fisher expands biologics manufacturing at 3 sites

March 21, 2019

With biopharmaceuticals dominating the drug development landscape, Thermo Fisher Scientific says it needs more capacity throughout its manufacturing network. To that end, its CDMO operations will invest $150 million in three sites. The company says the investments will provide additional capacity for sterile liquid and..

Bayer animal health sale could rake in $8B and bids from private equity: report

March 20, 2019

Ever since last November, when Bayer ended months of speculation and confirmed it would be casting off its animal health unit, investors have been waiting for details. Now, some hints are emerging about just how Bayer plans to exit its animal health business—and who might..

As Merck boosts R&D pact, NGM Bio gains Genentech, Lilly veteran as new R&D chief

March 20, 2019

It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials. The biotech sees Hsiao D. Lieu, M.D., become its new senior vice president and CMO, poaching him from..

Novartis’ Sandoz chief exits with ‘de-integration’ undone. Could a spinoff be next?

March 15, 2019

Novartis CEO Vas Narasimhan said in January that his company is focused on the “de-integration” of Sandoz from the rest of its operations. But now, the copycat drug unit’s CEO won’t see that plan through, triggering renewed speculation about a potential spinoff or sale. Richard..

Smith & Nephew moves further into regenerative medicine with $660M purchase of Osiris

March 14, 2019

Smith & Nephew has moved to absorb regenerative medicine developer Osiris Therapeutics in a $660 million deal that the company hopes will expand and accelerate its wound care business. Osiris’ portfolio includes bone graft, cartilage and skin substitutes—including its main growth drivers Grafix and Stravix,..

Novartis announces change in Sandoz leadership

March 14, 2019

Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019. Francesco Balestrieri, currently Region Head Europe, Sandoz, has been appointed ad-interim CEO Sandoz. He..

CLIENT PORTAL